← Back to Volume 7

Impact of the Pentavalent Meningococcal Conjugate Vaccine(NmCV-5) Targeting Serogroups A,C,Y,W, and X on the Sub-Saharan Africa Region

Yuxiang Zhang
pp.420-426 DOI: 10.62051/gmvqsc77 December 24, 2024
Download PDF
Abstract: Meningococcal disease poses a considerable public health burden in sub-Saharan Africa (SSA), particularly in the "meningitis belt". Although the rollout of the serogroup A meningococcal vaccine (MenAfriVac) has effectively contributed to a significant reduction in the incidence of group A meningitis, serogroups C, W, Y, and X are experiencing rising infection rates, highlighting the urgent need for new vaccines to address the threat posed by non-serogroup A Neisseria meningitidis. Considering this, Serum Institute of India Pvt Ltd., in partnership with PATH, developed a pentavalent conjugate vaccine (NmCV-5) containing capsular polysaccharides of meningococcal serogroups: A, C, W, X and Y, conjugated to a protein carrier, tetanus toxoid. In this paper, the epidemic trend of meningococcal and the development of NmCV-5 vaccine in SSA were analyzed by literature review. It has been shown that the NmCV-5 vaccine demonstrated good safety and immunogenicity against all serogars in clinical trials, especially significant protection against Neisseria meningitidis serogroup X. The single-dose schedule of the vaccine also improves roll-out feasibility in resource-limited Settings. However, the rollout of the vaccine still faces challenges such as poor infrastructure and insufficient public awareness.
Keywords: NmCV-5; Sub-Saharan Africa; Meningococcal disease.
APA Citation: Yuxiang Zhang (2024). Impact of the Pentavalent Meningococcal Conjugate Vaccine(NmCV-5) Targeting Serogroups A,C,Y,W, and X on the Sub-Saharan Africa Region. Transactions on Materials, Biotechnology and Life Sciences, 7(1), 420-426. https://doi.org/10.62051/gmvqsc77

References

  1. Nakamura, T., Cohen, A. L., Schwartz, S., Mwenda, J. M., Weldegebriel, G., Biey, J. N. M., Katsande, R., Ghoniem, A., Fahmy, K., Rahman, H. A., Videbaek, D., Daniels, D., Singh, S., Wasley, A., Rey-Benito, G., de Oliveira, L., Ortiz, C., Tondo, E., Liyanage, J. B. L., Sharifuzzaman, M., … Serhan, F. (2021). The Global Landscape of Pediatric Bacterial Meningitis Data Reported to the World Health Organization-Coordinated Invasive Bacterial Vaccine-Preventable Disease Surveillance Network, 2014-2019. The Journal of infectious diseases, 224(12 Suppl 2), S161–S173.
  2. Patel, J. C., Soeters, H. M., Diallo, A. O., Bicaba, B. W., Kadadé, G., Dembélé, A. Y., ... & MenAfriNet Consortium. (2019). MenAfriNet: a network supporting case-based meningitis surveillance and vaccine evaluation in the meningitis belt of Africa. The Journal of infectious diseases, 220(Supplement_4), S148-S154.
  3. Fernandez, K., Lingani, C., Aderinola, O. M., Goumbi, K., Bicaba, B., Edea, Z. A., ... & Ronveaux, O. (2019). Meningococcal meningitis outbreaks in the African meningitis belt after meningococcal serogroup A conjugate vaccine introduction, 2011–2017. The Journal of infectious diseases, 220(Supplement_4), S225-S232.
  4. Purmohamad, A., Abasi, E., Azimi, T., Hosseini, S., Safari, H., Nasiri, M. J., & Fooladi, A. A. I. (2019). Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microbial pathogenesis, 134, 103571.
  5. Viviani, S. (2022). Efficacy and effectiveness of the meningococcal conjugate Group A vaccine MenAfriVac® in preventing recurrent meningitis epidemics in Sub-Saharan Africa. Vaccines, 10(4), 617.
  6. Mustapha, M. M., & Harrison, L. H. (2018). Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges. Human Vaccines & Immunotherapeutics, 14(5), 1107-1115.
  7. Goldblatt, D. (2000). Conjugate vaccines. Clinical & Experimental Immunology, 119(1), 1-3.
  8. Marshall, G. S., Fergie, J., Presa, J., & Peyrani, P. (2022). Rationale for the development of a pentavalent meningococcal vaccine: a US-focused review. Infectious Diseases and Therapy, 11(3), 937-951.
  9. Purmohamad, A., Abasi, E., Azimi, T., Hosseini, S., Safari, H., Nasiri, M. J., & Fooladi, A. A. I. (2019). Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microbial pathogenesis, 134, 103571.
  10. Chen, W. H., Neuzil, K. M., Boyce, C. R., Pasetti, M. F., Reymann, M. K., Martellet, L., ... & Alderson, M. R. (2018). Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. The Lancet Infectious Diseases, 18(10), 1088-1096.
  11. Tapia, M. D., Sow, S. O., Naficy, A., Diallo, F., Haidara, F. C., Chaudhari, A., ... & Kulkarni, P. S. (2021). Meningococcal serogroup ACWYX conjugate vaccine in Malian toddlers. New England Journal of Medicine, 384(22), 2115-2123.
  12. Haidara, F. C., Umesi, A., Sow, S. O., Ochoge, M., Diallo, F., Imam, A., Traore, Y., Affleck, L., Doumbia, M. F., Daffeh, B., Kodio, M., Wariri, O., Traoré, A., Jallow, E., Kampmann, B., Kapse, D., Kulkarni, P. S., Mallya, A., Goel, S., Sharma, P., … Clarke, E. (2023). Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia. The New England journal of medicine, 388(21), 1942–1955.
  13. Steffen, R., & Caumes, E. (2024). Three novel pentavalent meningococcal vaccines. Journal of Travel Medicine, 31(1), taad152.
  14. See also WHO Meningitis Weekly Bulletin, https://www.who.int/publications/m/item/meningitis-weekly-bulletin-1-to-7-may-2023
  15. Haidara, F. C., Umesi, A., Sow, S. O., Ochoge, M., Diallo, F., Imam, A., ... & Clarke, E. (2023). Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. New England Journal of Medicine, 388(21), 1942-1955.
  16. Bangura, J. B., Xiao, S., Qiu, D., Ouyang, F., & Chen, L. (2020). Barriers to childhood immunization in sub-Saharan Africa: a systematic review. BMC public health, 20, 1-15.